RU2018138639A - Способ, чип и их применение - Google Patents
Способ, чип и их применение Download PDFInfo
- Publication number
- RU2018138639A RU2018138639A RU2018138639A RU2018138639A RU2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A
- Authority
- RU
- Russia
- Prior art keywords
- biomarkers
- week
- paragraphs
- weeks
- pancreatic cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 104
- 239000000090 biomarker Substances 0.000 claims 57
- 239000012634 fragment Substances 0.000 claims 44
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 36
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 36
- 201000002528 pancreatic cancer Diseases 0.000 claims 36
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 36
- 239000000523 sample Substances 0.000 claims 26
- 239000011230 binding agent Substances 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 230000001575 pathological effect Effects 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000002285 radioactive effect Effects 0.000 claims 6
- 239000013068 control sample Substances 0.000 claims 5
- -1 PRD14 Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 3
- 235000020958 biotin Nutrition 0.000 claims 3
- 239000011616 biotin Substances 0.000 claims 3
- 230000002255 enzymatic effect Effects 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 238000011275 oncology therapy Methods 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 238000011529 RT qPCR Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 238000011342 chemoimmunotherapy Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- 239000012099 Alexa Fluor family Substances 0.000 claims 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 1
- 241000839426 Chlamydia virus Chp1 Species 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- YCKRFDGAMUMZLT-IGMARMGPSA-N Fluorine-19 Chemical compound [19F] YCKRFDGAMUMZLT-IGMARMGPSA-N 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101001065609 Homo sapiens Lumican Proteins 0.000 claims 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 claims 1
- 101000992396 Homo sapiens Oxysterol-binding protein-related protein 3 Proteins 0.000 claims 1
- 101000591211 Homo sapiens Receptor-type tyrosine-protein phosphatase O Proteins 0.000 claims 1
- 101000695838 Homo sapiens Receptor-type tyrosine-protein phosphatase U Proteins 0.000 claims 1
- 101000838579 Homo sapiens Serine/threonine-protein kinase TAO1 Proteins 0.000 claims 1
- 101001099058 Homo sapiens Serine/threonine-protein phosphatase PGAM5, mitochondrial Proteins 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102000003815 Interleukin-11 Human genes 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 102100032114 Lumican Human genes 0.000 claims 1
- 101000716700 Mesobuthus martensii Toxin BmKT Proteins 0.000 claims 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101100381300 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) atp-5 gene Proteins 0.000 claims 1
- 102100032154 Oxysterol-binding protein-related protein 3 Human genes 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 claims 1
- 102100034086 Receptor-type tyrosine-protein phosphatase O Human genes 0.000 claims 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 1
- 102100028948 Serine/threonine-protein kinase TAO1 Human genes 0.000 claims 1
- 102100038901 Serine/threonine-protein phosphatase PGAM5, mitochondrial Human genes 0.000 claims 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 101150063583 UBP7 gene Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000000376 autoradiography Methods 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000005376 hepatoid adenocarcinoma Diseases 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- 229940055742 indium-111 Drugs 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 atom Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 229940097886 phosphorus 32 Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608192.9A GB201608192D0 (en) | 2016-05-10 | 2016-05-10 | Method, array and use thereof |
| GB1608192.9 | 2016-05-10 | ||
| PCT/EP2017/061202 WO2017194613A2 (en) | 2016-05-10 | 2017-05-10 | Method, array and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018138639A true RU2018138639A (ru) | 2020-06-10 |
| RU2018138639A3 RU2018138639A3 (enExample) | 2020-10-30 |
Family
ID=56297465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018138639A RU2018138639A (ru) | 2016-05-10 | 2017-05-10 | Способ, чип и их применение |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200011872A1 (enExample) |
| EP (2) | EP3455632A2 (enExample) |
| JP (2) | JP2019516981A (enExample) |
| KR (1) | KR20190005858A (enExample) |
| CN (1) | CN109564221A (enExample) |
| AU (1) | AU2017261762A1 (enExample) |
| BR (1) | BR112018073178A2 (enExample) |
| CA (1) | CA3022022A1 (enExample) |
| GB (1) | GB201608192D0 (enExample) |
| IL (1) | IL262824A (enExample) |
| MX (1) | MX2018013621A (enExample) |
| RU (1) | RU2018138639A (enExample) |
| WO (1) | WO2017194613A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| WO2022109105A1 (en) * | 2020-11-18 | 2022-05-27 | Pandion Operations, Inc. | Madcam targeted therapeutics and uses thereof |
| CA3202255A1 (en) | 2020-12-21 | 2022-06-30 | Hayley WARSINSKE | Markers for the early detection of colon cell proliferative disorders |
| WO2022204332A1 (en) * | 2021-03-24 | 2022-09-29 | Combangio, Inc. | Compositions comprising c-met agonist antibodies and methods for use in ocular treatment |
| CN117305244B (zh) * | 2023-03-28 | 2025-02-28 | 湖南省肿瘤医院 | 人胰腺癌细胞株及其应用 |
| CN120177800B (zh) * | 2025-05-23 | 2025-10-10 | 四川大学 | 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039578B1 (en) | 1980-05-02 | 1985-04-10 | Edward P. Davis | Leg aid device |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| ATE419533T1 (de) * | 2002-10-31 | 2009-01-15 | Hoffmann La Roche | Verfahren/präparat zur erkennung von pankreaskrebs |
| US9005613B2 (en) * | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| WO2007013360A2 (en) * | 2005-07-27 | 2007-02-01 | Oncotherapy Science, Inc. | Pancreatic cancer related gene cst6 and gabrp |
| WO2008117067A2 (en) * | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| JP5931874B2 (ja) * | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| GB201103726D0 (en) * | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2013052480A1 (en) * | 2011-10-03 | 2013-04-11 | The Board Of Regents Of The University Of Texas System | Marker-based prognostic risk score in colon cancer |
| WO2013106844A2 (en) * | 2012-01-13 | 2013-07-18 | Oncocyte Corporation | Methods and compositions for the treatment and diaginosis of pancreatic cancer |
| KR20140094180A (ko) * | 2013-01-21 | 2014-07-30 | 연세대학교 산학협력단 | 보체인자 b 단백질에 특이적으로 결합하는 폴리펩타이드 또는 항체를 포함하는 췌장암 진단용 조성물 |
| CA2902841A1 (en) * | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| CN105102637B (zh) * | 2013-04-17 | 2018-05-22 | Lg电子株式会社 | 提取胰腺癌诊断生物标志物的方法、用于该方法的计算装置、胰腺癌诊断生物标志物以及包含该生物标志物的胰腺癌诊断装置 |
| EP3054298B1 (en) * | 2013-10-01 | 2019-02-20 | Toray Industries, Inc. | Method for detecting pancreatic tumor |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| WO2015171736A2 (en) * | 2014-05-07 | 2015-11-12 | University Of Utah Research Foundation | Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma |
| KR20150129932A (ko) * | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
| CN105092845A (zh) * | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置 |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
-
2016
- 2016-05-10 GB GBGB1608192.9A patent/GB201608192D0/en not_active Ceased
-
2017
- 2017-05-10 KR KR1020187032184A patent/KR20190005858A/ko not_active Abandoned
- 2017-05-10 RU RU2018138639A patent/RU2018138639A/ru not_active Application Discontinuation
- 2017-05-10 CN CN201780028945.6A patent/CN109564221A/zh active Pending
- 2017-05-10 US US16/097,420 patent/US20200011872A1/en not_active Abandoned
- 2017-05-10 CA CA3022022A patent/CA3022022A1/en not_active Abandoned
- 2017-05-10 BR BR112018073178-1A patent/BR112018073178A2/pt not_active IP Right Cessation
- 2017-05-10 EP EP17725897.7A patent/EP3455632A2/en not_active Withdrawn
- 2017-05-10 EP EP21171277.3A patent/EP3907509A3/en not_active Withdrawn
- 2017-05-10 AU AU2017261762A patent/AU2017261762A1/en not_active Abandoned
- 2017-05-10 JP JP2018559285A patent/JP2019516981A/ja active Pending
- 2017-05-10 WO PCT/EP2017/061202 patent/WO2017194613A2/en not_active Ceased
- 2017-05-10 MX MX2018013621A patent/MX2018013621A/es unknown
-
2018
- 2018-11-06 IL IL262824A patent/IL262824A/en unknown
-
2021
- 2021-06-28 JP JP2021106544A patent/JP2021165745A/ja active Pending
- 2021-12-08 US US17/545,076 patent/US20220206004A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018013621A (es) | 2019-04-25 |
| GB201608192D0 (en) | 2016-06-22 |
| EP3455632A2 (en) | 2019-03-20 |
| JP2021165745A (ja) | 2021-10-14 |
| CA3022022A1 (en) | 2017-11-16 |
| IL262824A (en) | 2018-12-31 |
| RU2018138639A3 (enExample) | 2020-10-30 |
| EP3907509A3 (en) | 2021-12-29 |
| CN109564221A (zh) | 2019-04-02 |
| WO2017194613A2 (en) | 2017-11-16 |
| WO2017194613A3 (en) | 2017-12-21 |
| JP2019516981A (ja) | 2019-06-20 |
| US20220206004A1 (en) | 2022-06-30 |
| BR112018073178A2 (pt) | 2019-02-19 |
| US20200011872A1 (en) | 2020-01-09 |
| AU2017261762A1 (en) | 2018-11-15 |
| KR20190005858A (ko) | 2019-01-16 |
| EP3907509A2 (en) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018138639A (ru) | Способ, чип и их применение | |
| KR101788414B1 (ko) | 간암 조기 진단용 바이오마커 및 그 용도 | |
| JP2019516981A5 (enExample) | ||
| RU2019123695A (ru) | Способы, массивы и их применение | |
| KR102289278B1 (ko) | 췌장암 진단용 바이오마커 패널 및 그 용도 | |
| WO2008039774A1 (en) | Extracellular and membrane-associated prostate cancer markers | |
| JP6072768B2 (ja) | 川崎病の診断マーカーおよび治療標的 | |
| KR101478826B1 (ko) | 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트 | |
| CN109975549B (zh) | 肿瘤来源IgG在胰腺癌诊断或预后中的用途 | |
| CN105283763A (zh) | 用于前列腺癌的生物标志物检测中的方法和阵列 | |
| WO2012081007A2 (en) | Methods of diagnosing and treating pancreatic cancer | |
| CN107110848B (zh) | 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法 | |
| JP2025518766A (ja) | 胃癌発病可能性の予測のためのバイオマーカー及びその用途 | |
| US20140248637A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit of lung cancer | |
| KR102171189B1 (ko) | 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 활용 | |
| CN117120847A (zh) | 肺癌的检测方法 | |
| KR101054952B1 (ko) | 간암 진단 및 환자 생존기간 예측용 마커인 ｕｑｃｒｈ, 그를 포함하는 키트 및 상기 마커를 이용한 간암 환자 생존기간 예측 | |
| JP2007263896A (ja) | 肺癌患者の術後予後予測のための生物マーカー及びその方法 | |
| KR101878974B1 (ko) | 신장암 진단용 조성물과 진단 마커 검출 방법 | |
| KR102136747B1 (ko) | 장형 위암의 예후 진단 마커 | |
| EP3698138B1 (en) | Assay and kit for the diagnosis of ovarian carcinoma | |
| KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
| JP6769596B2 (ja) | 膀胱癌診断薬及び生体試料の判定方法 | |
| KR102770814B1 (ko) | 자궁경부암의 예후 및 동시항암화학방사선 요법에 대한 치료 반응 예측에 대한 바이오마커 및 이를 이용한 정보 제공방법 | |
| CN113789387B (zh) | 标志物在诊断腹主动脉瘤中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211220 |